June 2013 Issue of MMM
JUNE 2013 Issue
The actual amounts may be small, but the direction of the swing is undeniable
Click the above link to access the complete Digital Edition of the June 2013 issue, with all text, charts and pictures.
5 breakthroughs at the intersection of devices and diagnostics that promise to make healthcare more effective and accessible. Matthew Arnold reports
Don't be fooled by flat spend—big changes are happening. James Chase offers key insights from an exciting new study
As consumer mHealth apps have become more plentiful, Joe Shields asks whether we've all gone "app-crazy," or if apps have a real role to play ...
As doctors' needs evolve, message delivery must align more with their preferences. Mark Grove and Joanne Flynn share a fresh approach for meeting the challenges ...
"You can tell people to live a healthy lifestyle, but a lot of people don't know what that means"
Science is yielding all-oral therapies that can cure hepatitis C in three months, without injected interferon. But there are potential headwinds. Noah Pines sorts out ...
For the client-side market researcher, "doing more with less" is a mantra, if not a corporate way of life
There's been a paradigm shift among buy-side companies, which have finally accepted the fact that external R&D is going to be a big part of ...
The Justice Department has accused Novartis' US unit of offering opulent dinners and paying physicians as an enticement to prescribe its drugs.
A prescription morning sickness drug combining doxylamine succinate and pyridoxine hydrochloride is returning to US pharmacies after a 30-year absence.
News on Pfizer, Amgen, Eli Lilly and Merck
Med Ed Report
Boehringer Ingelheim and Eli Lilly rolled out a pre-launch med-ed campaign to differentiate their positioning in the SGLT2 diabetes drug class.
Navidea Biopharmaceuticals is launching Lymphoseek, its diagnostic agent used to check for cancer spread, with medical affairs, promotional education and CME aimed at the nuclear ...
News on the Australian Medical Association, Sanofi, GAME, Novartis and KnowledgePoint 360
Velcade has rolled out an "iPatient" sales app to help invigorate the brand
Professional physician network Doximity hit two milestones this spring: membership hit 160,000 US physicians and the network released an iPad app that will help doctors ...
News on Oxford University Press, Barash's Clinical Anesthesia and UBM Medica
What are some ways that pharma could use websites, analytics and social media to boost enrollment in clinical trials?
WedMD has revealed several changed that it has in the works following the departure of CEO Cavan Redmond
Reps remain the center of the universe when it comes to professional promotion, but new data show that non-personal promotion is gaining ground.
News on Pfizer, Google, Smart Patients and FDA
Genzyme is taking rare disease awareness to another level with a documentary film, dubbed "Facing Fabry Together," that follows four families grappling with the genetic ...
Pfizer, once a mighty powerhouse of DTC innovation, has been relegated (or should I say regulated?) to running an "ad-like object" for its new ADHD ...
Data from Kantar Media and Manhattan Research suggest that social media is increasingly being used to search for so-called "health" data.
A study, offers for the first time, according to researchers, empirical evidence of the link between a company's culture from a commercial-operations standpoint and revenue ...
Double-digit growth and a fragmented healthcare system in India have spurred consultancies and data firms, although experts say pricing for services varies widely.
Publicis Healthcare Communications Group (PHCG) is hoping to return to growth after a tame 2012, its CEO said.
CAHG is partnering with Diaceutics Limited to develop a practice around personalized medicines.
News on Digitas Health New York, Compass Healthcare Marketers, Valeant Pharmaceuticals, Edelman and Allergan
While there are successes in the battle for better adherence/compliance, we're losing the war
FDA director of drug evaluation and research Janet Woodcock says she is amazed that FDA has had more than 30 requests for its new breakthrough ...
Marketing 3.0 calls for thinking in parallel rather than following the linear path of traditional paradigms
Whether serious or humorous, the right "line" can stand alone, transcend the need for an accompanying visual, and become iconic in its own right.
Paul O'Neil, President, Ogilvy CommonHealth Wellness Marketing
At Work With
Tim Frank, Managing partner, Triple Threat Communications
Manufacturer and agency promotions and hires
The octane of the idea determines how well a digital tactic performs
Skill Sets (advertising section)
What does going "beyond the pill" actually mean? At MM&M's recent inaugural spring conference, audience members heard from real-world companies that are managing the organizational, technological, and promotional challenges inherent in this transition, such as partnering with health neophytes, harnessing technologies that allow deeper engagement with patients, and adopting a new commercial mindset to serve, not sell. Download here.
A wave of more effective anti-cancer drugs has set the oncology world on fire with enthusiasm. While many hail this as a new era, an equally vocal faction questions the money spent for the value gained. This medical and commercial trend report for marketers of anti-cancer modalities touches on many of the latest shifts that have expedited product launches and otherwise impacted promotion and reimbursement of these drugs. Click here.